Skip to main content
. 2021 Nov 29;193(47):E1798–E1806. doi: 10.1503/cmaj.210659

Table 2:

Results for the interventional autoregressive integrated moving average model summarizing the association of the COVID-19 pandemic and monthly age-standardized incidence rates for new pediatric cancer diagnoses per million population

Parameter ARIMA (p d q)(P D Q)12* Level shift intervention Trend change intervention


Estimate of β (95% CI) p value Estimate of β (95% CI) p value
Cancer type

 All cancers combined (1 0 0)(0 0 0)** 4.98 (−15.1 to 25.04) 0.6 −2.09 (−5.63 to 1.44) 0.25

 Leukemia and lymphoma (1 0 0)(0 0 0) 10.27 (−0.72 to 23.25) 0.1 −1.00 (−3.27 to 1.27) 0.4

 CNS tumour (0 0 0)(0 1 1)** −5.11 (−11.7 to 1.45) 0.1 NA

 Extracranial solid tumour (0 0 0)(0 1 1)** −1.33 (−11.4 to 8.73) 0.8 NA

Geographic region

 Atlantic§ (1 0 1)(0 0 0) 11.98 (0.38.3 to 62.22) 0.6 NA

 Quebec (1 0 1)(0 0 0) −16.0 (−51.1 to 19.12) 0.4 NA

 Ontario (2 0 0)(0 0 0) −7.09 (−32.6 to 18.42) 0.6 NA 0.7

 Prairies (0 1 1)(0 1 1) −38.7 (−126.0 to 48.41) 0.4 NA

 British Columbia (0 0 0)(0 0 0) 25.22 (−3.01 to 53.45) 0.09 NA

Note: ARIMA = autoregressive integrated moving average, ASIR = age-standardized incidence rate, CI = confidence interval, CNS = central nervous system, NA = not applicable.

*

For methodological considerations regarding ARIMA models, see Appendix 1, Supplement 2, available at www.cmaj.ca/lookup/doi/10.1503/cmaj.210659/tab-related-content.

The level change measures an immediate change after the onset of the pandemic.

The trend (slope) change measures a progressive increase or decrease in ASIRs in the pandemic period compared with the hypothetical continuations of the trends from the baseline period of March 2016 to February 2020.

§

Includes Nova Scotia, Prince Edward Island, Newfoundland and Labrador, and New Brunswick.

Includes Manitoba, Alberta and Saskatchewan.

**

Indicates that the trend change variable was not selected in the final model.